Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway

  • Int J Mol Sci. 2023 Apr 17;24(8):7373. doi: 10.3390/ijms24087373.
Stephen J Harwood  1 ,  Christopher R Smith  1 ,  J David Lawson  1 ,  John M Ketcham  1
Affiliations
  • 1. Mirati Therapeutics, 3545 Cray Court, San Diego, CA 92121, USA.
PMID: 37108538 DOI: 10.3390/ijms24087373
Abstract

Within the MAPK/Ras pathway, there exists a plethora of protein-protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much needed therapies for patients with KRAS-mutant driven cancers. In this review, we focus on recent strategies to inhibit RAS-signaling via disrupting PPIs associated with SOS1, Raf, PDEδ, Grb2, and Ras.

Keywords
KRAS; MAPK; RAS; X-ray crystallography; protein–protein interactions.
Products